Rcophth amd guidelines

The International Council of Ophthalmology (ICO) developed the ICO Guidelines for Diabetic Eye Care to serve a supportive and educational role for ophthalmologists and eye care providers worldwide. They are intended to improve

Age-related macular degeneration (AMD) is the most common cause of irreversible visual loss in the western world.1-5 Broadly, there are two types of AMD: dry or non-exudative AMD, and wet or exudative AMD. The dry form is characterised by drusen formation and a slow, progressive focal atrophy of the macular retinal pigment epithelium (RPE) and inner choroid. the RCOphth AMD guidelines in 2009. METHODS Participants A total of 4000 members of the Macular Society who joined after 1 January 2000 were selected from the mem-bership database using campaign management software (NFP CARE, Advance Computer Software Group). In Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update Praveen J Patel,1 Helen Devonport,2 Sobha Sivaprasad,1 Adam H Ross,3 Gavin Walters,4 Richard P Gale,5 Andrew J Lotery,6 Sajjad Mahmood,7 James S Talks,8 Jackie Napier9 1National Institute for Health Research Biomedical Research Centre at Moorfields Eye Age-related Macular Degeneration (AMD) is a long term condition which is the leading cause of sight loss in the UK. Sight loss often occurs quickly with the exudative ("wet") form of AMD but can be stabilised or improved in most cases with prompt treatment and timely monitoring. The main objective for an AMD service is [This recommendation is from ranibizumab and pegaptanib for the treatment of age-related macular degeneration (NICE technology appraisal guidance 155).] 1.5.9 Aflibercept solution for injection is recommended as an option for treating wet age-related macular degeneration only if: Advanced imaging yields a growing number of indicators. Angelica Ly BOptom (Hons) GradCertOcTher Senior Staff Optometrist, PhD candidate, Centr